IKT Stock Analysis: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$1.59
-0.09 (-5.36%)
▼
5d:
-8.62%
30d:
-22.44%
90d:
-20.5%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $1.59, which is considered oversold relative to its 30-day fair value range of $1.75 to $2.02.
Technical Outlook: Technically, IKT is in a uptrend. The price is currently testing key support at $1.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.71 (+240.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IKT is in a uptrend. The price is currently testing key support at $1.57. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.71 (+240.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.75 -
$2.02
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 240.1% below Wall St target ($5.71)
- CAUTION: Recommendation downgraded due to -8.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$1.75 -
$2.02
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.57
Resistance Level
$2.06
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.64
Wall Street Target
$5.71
(+240.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 1:32 PM ET
Data refreshes hourly during market hours. Next update: 2:32 PM
Data refreshes hourly during market hours. Next update: 2:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 60 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 61 BUY |
